|
1
|
Weinbren K and Mutum SS: Pathological
aspects of cholangiocarcinoma. J Pathol. 139:217–238. 1983.
View Article : Google Scholar
|
|
2
|
Patel T: Cholangiocarcinoma. Nat Clin
Pract Gastroenterol Hepatol. 3:33–42. 2006. View Article : Google Scholar
|
|
3
|
Burt AD, Portmann BC, Ishak KG, Scheuer
PJ, Anthony PP, et al: Tumors and tumor-like lesions of the liver
and the biliary tract: aetiology, epidemiology and pathology.
Pathology of the Liver. MacSween RNM: Churchill Livingstone;
London: pp. 711–775. 2002
|
|
4
|
Taylor-Robinson SD, Toledano MB, Arora S,
et al: Increase in mortality rates from intrahepatic
cholangiocarcinoma in England and Wales 1968–1998. Gut. 48:816–820.
2001.
|
|
5
|
Khan SA, Davidson BR, Goldin RD, et al:
Guidelines for the diagnosis and treatment of cholangiocarcinoma.
Gut. 61:1657–1669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vauthey JN and Blumgart LH: Recent
advances in the management of cholangiocarcinomas. Semin Liver Dis.
14:109–114. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blechacz B and Gores GJ:
Cholangiocarcinoma: advances in pathogenesis, diagnosis and
treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jarnagin WR and Shoup M: Surgical
management of cholangio- carcinoma. Semin Liver Dis. 24:189–199.
2004. View Article : Google Scholar
|
|
9
|
Zhang BH, Cheng QB, Luo XJ, Zhang YJ,
Jiang XQ, Zhang BH, Yi B, Yu WL, Wu MC, et al: Surgical therapy for
hiliarcholangiocarcinoma: analysis of 198 cases. Hepatobiliary
Pancreat Dis Int. 5:278–282. 2006.PubMed/NCBI
|
|
10
|
Morise Z, Sugioka A, Tokoro T, et al:
Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World
J Hepatol. 2:58–64. 2010.PubMed/NCBI
|
|
11
|
Iwatsuki S, Todo S, Marsh JW, et al:
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with
hepatic resection or transplantation. J Am Coll Surg. 187:358–364.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sirica AE: Cholangiocarcinoma: molecular
targeting strategies for chemoprevention and therapy. Hepatology.
41:5–15. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anderson CD, Pinson CW, Berlin J, Chari
RS, et al: Diagnosis and treatment of cholangiocarcinoma.
Oncologist. 9:43–57. 2004. View Article : Google Scholar
|
|
14
|
Aggarwal BB and Shishodia S: Molecular
targets of dietary agents for prevention and therapy of cancer.
Biochem Pharmacol. 71:1397–1421. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Russo GL: Ins and outs of dietary
phytochemicals in cancer chemoprevention. Biochem Pharmacol.
74:533–544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Naithani R, Huma LC, Moriarty RM,
McCormick DL, Mehta RG, et al: Comprehensive review of cancer
chemopreventive agents evaluated in experimental carcinogenesis
models and clinical trials. Curr Med Chem. 15:1044–1071. 2008.
View Article : Google Scholar
|
|
17
|
Kaefer CM and Milner JA: The role of herbs
and spices in cancer prevention. J Nutr Biochem. 19:347–361. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ortega R: Importance of functional foods
in the Mediterranean diet. Public Health Nutr. 9:1136–1140. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bartoli R, Fernandez-Banares F, Navarro E,
Castella E, et al: Effect of olive oil on early and late events of
colon carcinogenesis in rats: modulation of arachidonic acid
metabolism and local prostaglandin E2 synthesis. Gut.
46:191–199. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Owen RW, Giacosa A, Hull WE, Haubner R, et
al: The anti-oxidant/anticancer potential of phenolic compounds
isolated from olive oil. Eur J Cancer. 36:1235–1247. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Granados-Principal S, Quiles JL,
Ramirez-Tortosa CL, Sanchez-Rovira P, Ramirez-Tortosa MC, et al:
Hydroxytyrosol: from laboratory investigations to future clinical
trials. Nutr Rev. 68:191–206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ragione FD, Cucciolla V, Borriello A,
Pietra VD, et al: Hydroxytyrosol, a natural molecule occurring in
olive oil, induces cytochrome c-dependent apoptosis. Biochem
Biophys Res Commun. 278:733–739. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fabiani R, De Bartolomeo A, Rosignoli P,
Servili M, et al: Cancer chemoprevention by hydroxytyrosol isolated
from virgin olive oil through G1 cell cycle arrest and apoptosis.
Eur J Cancer Prev. 11:351–358. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
D’Angelo S, Ingrosso D, Migliardi V,
Sorrentino A, et al: Hydroxytyrosol, a natural antioxidant from
olive oil, prevents protein damage induced by long-wave ultraviolet
radiation in melanoma cells. Free Radic Biol Med. 38:908–919.
2005.PubMed/NCBI
|
|
25
|
Han J, Talorete TP, Yamada P, Isoda H, et
al: Anti-proliferative and apoptotic effects of oleuropein and
hydroxytyrosol on human breast cancer MCF-7 cells. Cytotechnology.
59:45–53. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Corona G, Deiana M, Incani A, Vauzour D,
Dessì MA, Spencer JP, et al: Hydroxytyrosol inhibits the
proliferation of human colon adenocarcinoma cells through
inhibition of ERK1/2 and cyclin D1. Mol Nutr Food Res. 53:897–903.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Saijyo S, Kudo T, Suzuki M, et al:
Establishment of a new extrahepatic bile duct carcinoma cell line,
TFK-1. Tohoku J Exp Med. 177:61–71. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Autret A and Martin SJ: Emerging role for
members of the Bcl-2 family in mitochondrial morphogenesis. Mol
Cell. 36:355–363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nicholson DW and Thornberry NA: Caspases:
killer proteases. Trends Biochem Sci. 22:299–306. 1997. View Article : Google Scholar
|
|
30
|
Kluck RM, Bossy WE, Green DR, Newmeyer DD,
et al: The release of cytochrome c from mitochondria: a primary
site for Bcl-2 regulation of apoptosis. Science. 275:1132–1136.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang X: The expanding role of mitochondria
in apoptosis. Genes Dev. 15:2922–2933. 2001.
|
|
32
|
de Groot RP, Coffer PJ and Koenderman L:
Regulation of proliferation, differentiation and survival by the
IL-3/IL-5/GM-CSF receptor family. Cell Signal. 10:619–628.
1998.PubMed/NCBI
|
|
33
|
Malemud CJ: Inhibitors of stress-activated
protein/mitogen activated protein kinase pathways. Curr Opin
Pharmacol. 7:339–343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Morrison DK and Davis RJ: Regulation of
MAP kinase signaling modules by scaffold proteins in mammals. Annu
Rev Cell Dev Biol. 19:91–118. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rennefahrt U, Janakiraman M, Ollinger R,
Troppmair J, et al: Stress kinase signaling in cancer: fact or
fiction? Cancer Lett. 217:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Prouillet C, Mazière JC, Mazière C, Wattel
A, Brazier M and Kamel S: Stimulatory effect of naturally occurring
flavonols quercetin and kaempferol on alkaline phosphatase activity
in MG-63 human osteoblasts through ERK and estrogen receptor
pathway. Biochem Pharmacol. 67:1307–1313. 2004. View Article : Google Scholar
|
|
37
|
Yin F, Giuliano AE, Law RE and Van Herle
AJ: Apigenin inhibits growth and induces G2/M arrest by modulating
cyclin-CDK regulators and ERK MAP kinase activation in breast
carcinoma cells. Anticancer Res. 21:413–420. 2001.PubMed/NCBI
|
|
38
|
Wruck CJ, Claussen M, Fuhrmann G, Römer L,
et al: Luteolin protects rat PC12 and C6 cells against
MPP+ induced toxicity via an ERK dependent
Keap1-Nrf2-ARE pathway. J Neural Transm (Suppl). 72:57–67. 2007.
View Article : Google Scholar : PubMed/NCBI
|
